Skip to main content
. Author manuscript; available in PMC: 2011 May 3.
Published in final edited form as: Cancer Res. 2010 Jan 12;70(2):471–480. doi: 10.1158/0008-5472.CAN-09-2863

Figure 6. Molecular mechanisms of PCa progression modulated by PGK1.

Figure 6

(A) CXCL12 or PGK1 alters the expression of α-SMA, MMP-2 , 3 in NSFs. Western blots were used to confirm the changes observed in selected mRNA levels identified in Supplemental Table 1. Whole cell lysates were immunoblotted with antibody to α-SMA, or antibodies to MMP-2 or MMP-3. Expression of α-SMA, MMP-2, 3 in CAFs were used as a positive control. The blots were stripped and reprobed with anti-α-tubulin antibody to confirm equal protein loading.

(B) Evaluation of the effects of expression of CXCL12 or PGK1 in NSFs on ERK or AKT signaling. After a 24-h serum withdrawal, PCa cells treated with CM derived from NSFCXCL12, NSFPGK1 and NSFControl were assayed for ERK or AKT signaling by Western blotting at various time points. Whole cell lysates were separated on SDS-PAGE and immunoblotted with antibodies to p-ERK (p-p44/p42) or p-AKT. The blots were stripped and reblotted with antibodies against total ERK (p44/p42) AKT, respectively (top).